Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

(2019) Yang Wang et al.   Scientific Reports

PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation

(2018) Xin Yao Qiu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma

(2018) Xinhua Song et al.   CLINICAL CANCER RESEARCH

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling

(2018) Yi Gao et al.   INTERNATIONAL JOURNAL OF CANCER

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

(2018) Rosemarie Tremblay-LeMay et al.   Journal of Hematology & Oncology

Inhibitors of the PD-1 Pathway in Tumor Therapy

(2018) Martin W. LaFleur et al.   JOURNAL OF IMMUNOLOGY

Dermatofibrosarcoma Protuberans: A Retrospective Study of Clinicopathological Features and Related Akt/mTOR, STAT3, ERK, Cyclin D1, and PD-L1 Expression

(2018) Sunyoung Park et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

PD-L1 expression according to the EGFR status in primary lung adenocarcinoma

(2018) Kazuki Takada et al.   LUNG CANCER

Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels

(2018) LiJun Xu et al.   Molecular Oncology

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

(2018) Jake S. O’Donnell et al.   SEMINARS IN CANCER BIOLOGY

Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation

(2018) Genevieve P Hartley et al.   Cancer Immunology Research

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

(2018) Lisa Derosa et al.   OncoImmunology

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances

(2018) Alphonse E. Sirica et al.   HEPATOLOGY

Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma

(2018) Xue Han et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Interrogating PI3K to induce PD-L1 expression in oral carcinoma.

(2018) Sanjay Chandrasekaran et al.   JOURNAL OF CLINICAL ONCOLOGY

The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies

(2018) Catherine Rolvering et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model

(2018) Jibin Li et al.   MEDICAL SCIENCE MONITOR

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report

(2018) Haibo Mou et al.   BMC CANCER

Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer

(2018) Yanhua Wu et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

High PD‑L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy

(2018) Chenxue Jiang et al.   Oncology Letters

Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses

(2018) Ying Zhu et al.   Cancer Management and Research

A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1)

(2017) Raffaele Addeo   Expert Review of Anticancer Therapy

Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells

(2017) Xun Wang et al.   IMMUNOLOGY LETTERS

A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma

(2017) Naoya Maekawa et al.   Scientific Reports

IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma

(2017) Ji Wook Moon et al.   Scientific Reports

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma

(2016) Curtis A. Clark et al.   CANCER RESEARCH

Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner

(2016) Jessica Pinno et al.   CELLULAR SIGNALLING

Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma

(2016) Dan Høgdall et al.   DIGESTIVE DISEASES

Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling

(2016) Feng Liu et al.   Scientific Reports

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure

(2013) Hee Yeon Kim et al.   JOURNAL OF GASTROENTEROLOGY